Key result
The Matrix P plus de-cellularised pulmonary valve resulted in a 38% re-operation rate due to obstructed grafts at a median follow-up of 10 months.
Why the study?
Does the Matrix P plus de-cellularised tissue-engineered pulmonary valve provide safe and durable right ventricular outflow tract reconstruction in patients with congenital heart disease?
Observational (n=16)
Does the Matrix P plus de-cellularised tissue-engineered pulmonary valve provide safe and durable right ventricular outflow tract reconstruction in patients with congenital heart disease?
The Matrix P plus de-cellularised pulmonary valve is associated with a high rate of early failure and obstruction, suggesting it is not an ideal conduit for right ventricular outflow tract reconstruction.
No takes yet. Share an insight, caveat, or question.
Early failures warrant caution in conduit choice; leaves open the durability of decellularized valves for congenital RVOT reconstruction.
Rüffer et al. (2010) conducted an observational in Congenital heart disease requiring right ventricular outflow tract reconstruction (n=16). Xenogenous de-cellularised tissue-engineered pulmonary valve (Matrix P plus) was evaluated on Re-operation due to obstructed grafts. The Matrix P plus de-cellularised pulmonary valve resulted in a 38% re-operation rate due to obstructed grafts at a median follow-up of 10 months.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: